Sagimet Biosciences Announces Presentations at Metabolic Symposium

Got story updates? Submit your updates here. ›

Sagimet Biosciences, a clinical-stage biopharmaceutical company, announced that it will be presenting data from its Phase 2b FASCINATE-2 trial of denifanstat in MASH at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium. The company also disclosed an inducement grant of stock options to a newly hired employee.

Why it matters

Sagimet's denifanstat is a potential treatment for MASH, a progressive liver disease that affects over 265 million people worldwide. The data being presented at the symposium could provide insights into the drug's mechanism of action and its potential as a therapeutic option for MASH patients.

The details

The poster and oral presentations will focus on the impact of denifanstat on bile acid levels in MASH patients. Elevated bile acid levels have been associated with metabolic disorders like MASH and type 2 diabetes. The data from the FASCINATE-2 trial showed that denifanstat-treated MASH patients who were histological responders for both fibrosis regression and MASH resolution had significant reductions in glycine- and taurine-conjugated bile acids at 26 weeks. These findings suggest that bile acid levels could potentially be used as a biomarker to monitor response to denifanstat treatment.

• The Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium will be held from April 12-15, 2026 in Vancouver, BC, Canada.
• The inducement grant of 9,600 stock options was approved by Sagimet's Compensation Committee on April 3, 2026.

What’s next

Sagimet plans to develop a combination of denifanstat and resmetirom for patients with MASH cirrhosis (F4).